
Recurrent high-grade glioma (HGG) is associated with an extremely poor prognosis, particularly in patients with IDH-wildtype disease, whose median overall survival (OS) is only 6–10 months. Although targeted therapies have made progress, treatment of central nervous system (CNS) tumors remains extremely challenging because of the physiological barrier posed by the blood–brain barrier (BBB). At the 2026 European Society for Medical Oncology (ESMO) Congress, the team led by Professor Wenbin Li, Head of the Department of Neuro-Oncology at Beijing GoBroad Hospital, presented two research findings: an oral presentation of phase I data on the novel BRAF inhibitor HSK42360 in recurrent glioma, and large-scale prospective multicenter data on teniposide combined with platinum-based chemotherapy for recurrent HGG. On October 31, the 6th iHope Innovation Medicine Forum was held, focusing on the development of an Academic Research Organization (ARO) clinical research system and showcasing GoBroad Hospital's capabilities in building international multicenter clinical research networks and translating cutting-edge technologies into clinical practice. In this article, Professor Wenbin Li discusses breakthroughs in the clinical translation of innovative drugs and the evolving landscape of neuro-oncology treatment from the perspectives of translational medicine and clinical research.